AOC 1001 is based on Avidity’s Antibody Oligonucleotide Conjugates (AOCs
) platform, designed to treat diseases of high unmet need by combining the tissue selectivity of monoclonal antibodies (mAbs) with the precision of oligonucleotide therapies . . .
The post RNA in Its DNA: Avidity Biosciences Combines mAb Selectivity, Oligonucleotide Precision appeared first on GEN – Genetic Engineering and Biotechnology News.
